Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

June 2026

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions
EFFECTIVE 1 JUNE 2026

- Beta-HCG low sensitivity urine test kit (CheckTop) midstream – price increase
- Colestyramine (Questran Light (Neon)) powder for oral suspension 4 g sachet – new listing
- Cyclizine lactate (Hameln) inj 50 mg per ml, 1 ml ampoule – price increase
- Doxorubicin hydrochloride (Adriamycin) inj 2 mg per ml, 100 ml vial – new listing
- Droperidol (Droperidol Panpharma) inj 2.5 mg per ml, 1 ml ampoule – new listing
- Efavirenz with emtricitabine and tenofovir disoproxil (TEEVIR (India)) tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate) – new listing
- Elexacaftor with tezacaftor, ivacaftor and ivacaftor (Trikafta) – amended restriction criteria
  - Tab elexacaftor 100 mg with tezacaftor 50 mg, ivacaftor 75 mg (56) and ivacaftor 150 mg (28)
  - Tab elexacaftor 50 mg with tezacaftor 25 mg, ivacaftor 37.5 mg (56) and ivacaftor 75 mg (28)
  - Oral granules elexacaftor 100 mg with tezacaftor 50 mg, ivacaftor 75 mg (28) and ivacaftor 75 mg (28), sachets
  - Oral granules elexacaftor 80 mg with tezacaftor 40 mg, ivacaftor 60 mg (28) and ivacaftor 59.5mg (28), sachets
- Ezetimibe with simvastatin (Vytorin) tab 10 mg with simvastatin 80 mg – new listing
- Glucose [Dextrose] (HypoPak Glucose) oral soln 15 g per 80 ml sachet – price increase
- Ivacaftor (Kalydeco) tab 150 mg, oral granules 13.4 mg, 25 mg, 50 mg and 75 mg, sachet – amended restriction criteria
- Montelukast (Montelukast Paediatric (Relonchem)) tab 5 mg – amended brand name
- Nimodipine (Nimorhage) tab 30 mg – new listing
- Oestradiol valerate (Progynova) tab 2 mg – new Pharmacode listing
- Paracetamol (Noumed) oral liq 120 mg per 5 ml, 200 ml – new listing and addition of PSS
- Paracetamol (Ethics) oral liq 120 mg per 5 ml, 200 ml – to be delisted 1 November 2026
- Progesterone (Utrogestan) cap 100 mg – new Pharmacode listing
- Ramipril (Ramipril Viatris) tab 2.5 mg – new listing
- Ribociclib (Kisqali) tab 200 mg, 21, 42 and 63 tab pack – new Pharmacode listing
- Risperidone (Risperidone Sandoz) tab 0.5 mg and 2 mg – new listing

Summary of decisions – effective 1 June 2026 (continued)

- Rizatriptan (Rizatriptan Viatris) tab orodispersible 10 mg – new listing
- Rotavirus oral vaccine (Rotarix) oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, squeezable tube – delisted 1 June 2026
- Sodium bicarbonate (Sodibic) cap 840 mg – Pharmacode 2085992 delisted 1 June 2026
- Trimethoprim with sulphamethoxazole [co-trimoxazole] (Deprim) oral liq 8 mg with sulphamethoxazole 40 mg per ml, 100 ml – new Pharmacode listing
- Vanzacaftor with tezacaftor and deutivacaftor (Alyftrek) tab vanzacaftor 4 mg with tezacaftor 20 mg and deutivacaftor 50 mg and tab vanzacaftor 10 mg with tezacaftor 50 mg and deutivacaftor 125 mg – amended restriction criteria
- Venetoclax (Venclexta) tab 14 × 10 mg, 7 × 50 mg, 21 × 100 mg, tab 10 mg, tab 50 mg and tab 100 mg – amended restriction criteria
- Water (Multichem) inj 10 ml ampoule – price increase and addition of PSS
- Water (Fresenius Kabi) inj 10 ml ampoule – delisted 1 June 2026

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 June 2026

ALIMENTARY TRACT AND METABOLISM

9	GLUCOSE [DEXTROSE] (↑ price)			
	Oral soln 15 g per 80 ml sachet	75.00	50	HypoPak Glucose

BLOOD AND BLOOD FORMING ORGANS

43	WATER (↑ price and addition of PSS)			
	Inj 10 ml ampoule – **5% DV Nov-26 to 2028**	9.50	50	**Multichem**
	Note – Fresenius Kabi inj 10 ml ampoule delisted 1 June 2026.			
43	SODIUM BICARBONATE (delisted)			
	Cap 840 mg	8.52	100	Sodibic
	Note – This delist applies to Pharmacode 2085992, delisted 1 June 2026.			

CARDIOVASCULAR SYSTEM

45	RAMIPRIL (new listing)			
	Tab 2.5 mg	5.50	30	Ramipril Viatris
50	NIMODIPINE (new listing)			
	Tab 30 mg	344.83	100	Nimorhage
54	COLESTYRAMINE (new listing)			
	Powder for oral suspension 4 g sachet	61.50	50	Questran Light (Neon)
54	EZETIMIBE WITH SIMVASTATIN (new listing)			
	Tab 10 mg with simvastatin 80 mg	14.27	30	Vytorin

GENITO-URINARY SYSTEM

77	PROGESTERONE (new listing)			
	Cap 100 mg	14.85	30	Utrogestan
	Note – This is a new Pharmacode listing 2730340			

HORMONE PREPARATIONS

82	OESTRADIOL VALERATE (new listing)			
	Tab 2 mg	8.24	56	Progynova
	Note – this is a new Pharmacode listing, 2730979.			

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 June 2026 (continued)

INFECTIONS

98 TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE] (new listing)
Oral liq 8 mg with sulphamethoxazole 40 mg per ml
– **5% DV Aug-25 to 2028** ..... 4.95 100 ml **Deprim**
Note – this is a new Pharmacode listing, 2730847.

106 EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL (new listing)
➔ Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate) ..... 106.88 30 TEEVIR (India)

NERVOUS SYSTEM

127 PARACETAMOL (brand change and addition of PSS)
Oral liq 120 mg per 5 ml – **5% DV Nov-26 to 2028** ..... 3.18 200 ml **Noumed**
Note – Paracetamol (Ethics) oral liq 120 mg per 5 ml to be delisted from 1 November 2026.

134 RIZATRIPTAN (new listing)
Tab orodispersible 10 mg ..... 4.84 30 Rizatriptan Viatris

135 CYCLIZINE LACTATE (↑ price)
Inj 50 mg per ml, 1 ml ampoule ..... 17.86 10 Hameln

135 DROPERIDOL (new listing)
Inj 2.5 mg per ml, 1 ml ampoule ..... 43.85 10 Droperidol Panpharma

137 RISPERIDONE (new listing)
Tab 0.5 mg ..... 4.01 60 Risperidone Sandoz
Tab 2 mg ..... 5.38 60 Risperidone Sandoz

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

153 DOXORUBICIN HYDROCHLORIDE (new listing)
Inj 2 mg per ml, 100 ml vial ..... 164.50 1 Adriamycin

Changes to Section H Part II – effective 1 June 2026 (continued)

160 VENETOCLAX (amended restriction criteria – affected criteria shown only)

➔Tab 14 × 10 mg, 7 × 50 mg, 21 × 100 mg	1,771.86	42	Venclexta
➔Tab 10 mg	13.68	2	Venclexta
➔Tab 50 mg	239.44	7	Venclexta
➔Tab 100 mg	8,209.41	120	Venclexta

Restricted

Initiation – previously untreated chronic lymphocytic leukaemia in combination with obinutuzumab

Either:

1 Individual is currently on treatment with venetoclax and obinutuzumab and met all of the following criteria prior to commencing treatment; or

2 All of the following:

2.1 Individual has previously untreated chronic lymphocytic leukaemia; and

2.2 Venetoclax is to be administered with obinutuzumab; and

2.3 Venetoclax is to be used to a maximum dose of 400 mg and for a total of 12 (28 day) cycles*.

~~Note: *maximum number of cycles refers to 12 cycles of full dose venetoclax, in addition to the initial 5-week dose ramp-up period.~~

Initiation – previously untreated chronic lymphocytic leukaemia in combination with ibrutinib

Either:

1 Individual is currently on treatment with venetoclax and/or ibrutinib and met all of the following criteria prior to commencing treatment; or

2 All of the following:

2.1 Individual has previously untreated chronic lymphocytic leukaemia; and

2.2 Venetoclax is to be administered in combination with ibrutinib; and

2.3 Venetoclax is to be used to a maximum dose of 400 mg and for a total of 12 (28 day) cycles*.

~~Note: *maximum number of cycles refers to 12 cycles of full dose venetoclax, in addition to the initial 5-week dose ramp-up period.~~

170 RIBOCICLIB (new listing)

➔Tab 200 mg	1,883.00	21	Kisqali
	3,767.00	42	Kisqali
	5,650.00	63	Kisqali

Note – These are new Pharmacode listings 2728133 (21 pack), 2728141 (42 pack) and 2728168 (63 pack)

RESPIRATORY SYSTEM AND ALLERGIES

270 MONTELUKAST (amended brand name)

Tab 5 mg	3.10	28	**Montelukast Paediatric (**Relonchem**)**

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 June 2026 (continued)

272 ELEXACAFTOR WITH TEZACAFTOR, IVACAFTOR AND IVACAFTOR (amended restriction criteria)

➔Tab elexacaftor 50 mg with tezacaftor 25 mg, ivacaftor 37.5 mg (56) and ivacaftor 75 mg (28)	27,647.39	84	Trikafta
➔Tab elexacaftor 100 mg with tezacaftor 50 mg, ivacaftor 75 mg (56) and ivacaftor 150 mg (28)	27,647.39	84	Trikafta
➔Oral granules elexacaftor 80 mg with tezacaftor 40 mg, ivacaftor 60 mg (28) and ivacaftor 59.5mg (28), sachets	27,647.39	56	Trikafta
➔Oral granules elexacaftor 100 mg with tezacaftor 50 mg, ivacaftor 75 mg (28) and ivacaftor 75 mg (28), sachets	27,647.39	56	Trikafta

Restricted
Initiation
All of the following:
1 Patient has been diagnosed with cystic fibrosis; and
2 Either:
  2.1 Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental allele); or
  2.2 Patient has a sweat chloride value of at least 60 mmol/L; and
3 Either:
  3.1 Patient has a heterozygous or homozygous F508del mutation; or
  3.2 Patient has a mutation responsive to elexacaftor/tezacaftor/ivacaftor (see note); and
4 The treatment must be the sole funded CFTR modulator therapy for this condition; and
5 Treatment with elexacaftor/tezacaftor/ivacaftor must be given concomitantly with standard therapy for this condition.
Note: Eligible mutations are listed in the Food and Drug Administration (FDA) Trikafta prescribing information
~~https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212273s015lbl.pdf~~
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212273s014lbl.pdf

272 IVACAFTOR (amended restriction criteria)

➔Tab 150 mg	29,386.00	56	Kalydeco
➔Oral granules 13.4 mg, sachet	29,386.00	56	Kalydeco
➔Oral granules 25 mg, sachet	29,386.00	56	Kalydeco
➔Oral granules 50 mg, sachet	29,386.00	56	Kalydeco
➔Oral granules 75 mg, sachet	29,386.00	56	Kalydeco

Restricted
Initiation
All of the following:
1 Patient has been diagnosed with cystic fibrosis; and
2 Either:
  2.1 Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental allele); or
  2.2 Patients must have a sweat chloride value of at least 60 mmol/L; and
3 ~~Patient must have at least one mutation on the list of CFTR mutations that produce CFTR protein and are known to be responsive to ivacaftor**; and~~ **Patient has a mutation responsive to ivacaftor (see note); and**
4 Treatment with ivacaftor must be given concomitantly with standard therapy for this condition; and
5 The dose of ivacaftor will not exceed one tablet or one sachet twice daily.
Note:~~**~~ Mutations listed in Table 3 of the Food and Drug Administration (FDA) Ivacaftor prescribing information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203188s038lbl.pdf

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

Changes to Section H Part II – effective 1 June 2026 (continued)

273 VANZACAFTOR WITH TEZACAFTOR AND DEUTIVACAFTOR (amended restriction criteria)

➔Tab vanzacaftor 4 mg with tezacaftor 20 mg and deutivacaftor 50 mg ..... 29,029.76 84 Alyftrek

➔Tab vanzacaftor 10 mg with tezacaftor 50 mg and deutivacaftor 125 mg ..... 29,029.76 56 Alyftrek

Restricted
Initiation
All of the following:
1 Patient has been diagnosed with cystic fibrosis; and
2 Either:
  2.1 Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental allele); or
  2.2 Patient has a sweat chloride value of at least 60 mmol/L; and
3 Either:
  3.1 Patient has a heterozygous or homozygous F508del mutation; or
  3.2 Patient has a mutation responsive to vanzacaftor/tezacaftor/deutivacaftor (see note); and
4 The treatment must be the sole funded CFTR modulator therapy for this condition; and
5 Treatment with vanzacaftor/tezacaftor/deutivacaftor must be given concomitantly with standard therapy for this condition.

Note: Eligible mutations are listed in the in the Food and Drug Administration (FDA) Alyftrek prescribing information ~~https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218730s002lbl.pdf~~ **https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218730s001lbl.pdf**

VACCINES

321 ROTAVIRUS ORAL VACCINE (delisted)

➔Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, squeezable tube ..... 0.00 10 Rotarix

Note – Rotarix oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, squeezable tube delisted 1 June 2026.

OPTIONAL PHARMACEUTICALS

323 BETA-HCG LOW SENSITIVITY URINE TEST KIT (↑ price)

Note: For use in abortion services only.

Midstream ..... 17.47 1 test CheckTop

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 May 2026

CARDIOVASCULAR SYSTEM

56	HYDRALAZINE HYDROCHLORIDE (new listing)			
	Inj 20 mg per ml, 1 ml vial	283.00	25	Eugia

MUSCULOSKELETAL SYSTEM

121	NAPROXEN (new listing)			
	Tab 250 mg	3.92	50	Inza
	Tab 500 mg	6.89	50	Inza
125	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (new listing)			
	Spray 10% – **5% DV Feb-26 to 2028**	82.90	50 ml	**Xylocaine**

NERVOUS SYSTEM

137	OLANZAPINE (new listing)			
	Tab orodispersible 5 mg	3.93	28	APO-Olanzapine
	Tab orodispersible 10 mg	4.49	28	APO-Olanzapine

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

152	THIOTEPA (new listing)			
	Inj 100 mg vial	1,800.00	1	Thiotepa-Reach

Index
Pharmaceuticals and brands

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government